Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports a material definitive agreement entered into on July 6, 2015, with a report date of July 10, 2015. The filing details an amended and restated development and manufacturing services agreement with Agilent Technologies, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a contractual agreement rather than financial performance metrics.
Material Changes and Agreement Terms
- Agreement Scope: Agilent will manufacture and supply a specified percentage of active pharmaceutical ingredients (APIs) for Alnylam's products in clinical development and future agreed-upon products.
- Ordering Mechanism: Alnylam must provide rolling quarterly forecasts. A portion of these forecasts constitutes binding firm orders, while Agilent must reserve capacity for firm orders and a percentage of non-binding forecasts.
- Pricing Structure: Prices are determined per statement of work. Firm order prices are fixed. Non-binding portion price increases are subject to caps. Prices may be adjusted for documented raw material cost changes, subject to a cap.
- Term: The initial term is four years, with automatic renewal terms of two years unless terminated earlier.
- Commercial Supply: The parties agreed to negotiate in good faith for a separate commercial manufacturing supply agreement, including a specified minimum purchase commitment.
Guidance, Risks, and Termination Rights
The filing outlines specific termination rights and contingencies:
- Termination for Cause: Either party may terminate for material breach or bankruptcy.
- Change of Control: Alnylam may terminate the agreement with 15 months' prior written notice if Agilent undergoes a change of control, valid for one year after such event.
- Regulatory Failure: Alnylam may terminate any statement of work if Agilent fails to obtain or maintain material licenses or approvals.
- Standard Provisions: The agreement includes compliance with Good Manufacturing Practices (GMP), regulatory cooperation, indemnification, and confidentiality.
Investor Verification Checklist
- Verify the specific percentage of API supply committed under the agreement.
- Confirm the pricing caps and raw material adjustment thresholds defined in the statements of work.
- Monitor the progress of negotiations for the separate commercial manufacturing supply agreement and minimum purchase commitments.
- Assess Agilent's capacity to meet the reserved requirements for both firm and non-binding forecast portions.